Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in
Akeso Inc. reported positive overall survival results from the HARMONi-2 study, showing ivonescimab monotherapy outperformed pembrolizumab in PD-L1-positive advanced NSCLC. Summit Therapeutics (SMMT) noted the findings, with ivonescimab approved in China and under investigation in other regions. The study's hazard ratio was 0.51 (p<0.0001). Summit is conducting further trials, including HARMONi-7 for PD-L1 high-expressing NSCLC.
How this was made
The 30-second read
Why it matters
The OS benefit reported in HARMONi-2 is the first such data for this molecule, potentially unlocking U.S. and EU market opportunities.
Market read
First disclosure of statistically significant overall survival data could drive short‑term price moves and long‑term valuation uplift for Summit and its partner.
What to watch
The drug is still investigational outside China; any delay in FDA filing or negative safety signals could dampen upside.
Background
Summit Therapeutics partners with Akeso to develop ivonescimab, a bispecific antibody targeting PD‑1 and VEGF, currently approved only in China.
Ticker impact
Summit Therapeutics (NASDAQ:SMMT) announced positive overall survival data for ivonescimab versus pembrolizumab in the Phase III HARMONi-2 trial.
Potential short‑term upside of 5‑10% on news release, with longer‑term upside if U.S./EU filings follow.
First disclosure of statistically significant OS benefit; market has not priced this data yet.
Market effects
Strengthens the immuno‑oncology bispecific antibody space, may lift peers developing PD‑1/VEGF combos.
Positive for Chinese biotech sector and for U.S. investors tracking Summit Therapeutics.
Adds a new potential first‑in‑class therapy to the global lung‑cancer treatment landscape.
Counterpoint
If regulatory pathways in the U.S. and Europe remain uncertain, the hype may be overstated and the stock could face volatility.
Key entities
- CompanySummit Therapeutics Inc.
U.S. biotech developing ivonescimab (SMT112).
- CompanyAkeso Inc.
Chinese biotech partner holding Chinese NMPA approval for ivonescimab.
